Proteolytic Processing of Marburg Virus Glycoprotein

By Volchkov V.E.   Volchkova V.A.   Stroher U.   Becker S.   Dolnik O.   Cieplik M.   Garten W.   Klenk H.-D.   Feldmann H.  

Virology, Vol. 268, Iss. 1, 2000-03 ,pp. : 1-6

Elsevier

Access to resources Recommend Favorite

Antigenicity and Vaccine Potential of Marburg Virus Glycoprotein Expressed by Baculovirus Recombinants

By Hevey M.   Negley D.   Geisbert J.   Jahrling P.   Schmaljohn A.  

Virology, Vol. 239, Iss. 1, 1997-12 ,pp. : 206-216

Elsevier

Access to resources Recommend Favorite

Vaccine Potential of Ebola Virus VP24, VP30, VP35, and VP40 Proteins

By Wilson J.A.   Bray M.   Bakken R.   Hart M.K.  

Virology, Vol. 286, Iss. 2, 2001-08 ,pp. : 384-390

Elsevier

Access to resources Recommend Favorite

Phosphorylation of Marburg Virus VP30 at Serines 40 and 42 Is Critical for Its Interaction with NP Inclusions

By Modrof J.   Moritz C.   Kolesnikova L.   Konakova T.   Hartlieb B.   Randolf A.   Muhlberger E.   Becker S.  

Virology, Vol. 287, Iss. 1, 2001-08 ,pp. : 171-182

Elsevier

Access to resources Recommend Favorite

Characterization of monoclonal antibodies to Marburg virus (strain Musoke) glycoprotein and identification of two protective epitopes

By Hevey M.   Negley D.   Schmaljohn A.  

Virology, Vol. 314, Iss. 1, 2003-09 ,pp. : 350-357

Elsevier

Access to resources Recommend Favorite